IL6 and cholangiocarcinoma: Accordingly, it has been shown that the pharmacological inhibition of IL-6 trans-signaling via the administration of recombinant sgp130Fc increased tumor cell survival, proliferation, and migration, suggesting that IL-6 signaling can be associated with a better CCA prognosis [159].